Sionna Therapeutics, Inc. (SION)
3.60
-0.20
(-5.26%)
USD |
NASDAQ |
Oct 23, 16:00
3.595
0.00 (0.00%)
After-Hours: 20:00
Sionna Therapeutics Enterprise Value : -40.37M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | -40.37M |
| October 22, 2026 | -31.34M |
| October 21, 2026 | -28.18M |
| October 20, 2026 | -15.53M |
| October 19, 2026 | -21.85M |
| October 16, 2026 | -27.27M |
| October 15, 2026 | -18.69M |
| October 14, 2026 | -18.24M |
| October 13, 2026 | -5.143M |
| October 12, 2026 | 8.858M |
| October 09, 2026 | 18.34M |
| October 08, 2026 | 18.34M |
| October 07, 2026 | 14.73M |
| October 06, 2026 | 11.57M |
| October 05, 2026 | 16.08M |
| October 02, 2026 | 18.79M |
| October 01, 2026 | 27.38M |
| September 30, 2026 | 34.60M |
| September 29, 2026 | 29.63M |
| September 28, 2026 | 28.28M |
| September 25, 2026 | 33.25M |
| September 24, 2026 | 33.25M |
| September 23, 2026 | 45.89M |
| September 22, 2026 | 68.93M |
| September 21, 2026 | 68.02M |
| Date | Value |
|---|---|
| September 18, 2026 | 66.22M |
| September 17, 2026 | 121.32M |
| September 16, 2026 | 114.99M |
| September 15, 2026 | 107.77M |
| September 14, 2026 | 170.09M |
| September 11, 2026 | 151.58M |
| September 10, 2026 | 141.19M |
| September 09, 2026 | 134.87M |
| September 08, 2026 | 126.74M |
| September 04, 2026 | 121.32M |
| September 03, 2026 | 101.90M |
| September 02, 2026 | 127.19M |
| September 01, 2026 | 88.80M |
| August 31, 2026 | 69.38M |
| August 28, 2026 | 62.15M |
| August 27, 2026 | 70.73M |
| August 26, 2026 | 75.70M |
| August 25, 2026 | 79.31M |
| August 24, 2026 | 49.51M |
| August 21, 2026 | 35.96M |
| August 20, 2026 | 46.34M |
| August 19, 2026 | 79.31M |
| August 18, 2026 | 65.31M |
| August 17, 2026 | 63.96M |
| August 14, 2026 | 88.80M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Vertex Pharmaceuticals, Inc. | 126.85B |
| Capricor Therapeutics, Inc. | 197.70M |
| ARS Pharmaceuticals, Inc. | 353.57M |
| ACADIA Pharmaceuticals, Inc. | 2.514B |
| Immunic, Inc. | -53.43M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -29.89M |
| Total Expenses (Quarterly) | 29.89M |
| EPS Diluted (Quarterly) | -0.6619 |
| Earnings Yield | -60.25% |
| Normalized Earnings Yield | -60.25 |